Disease trajectory intelligence

Predict with Clarity.

The intelligence layer for predicting disease transitions before they become irreversible.

SubscribeSee it work

Method

How Alera works.

One longitudinal profile. One dynamic model. One interpretable output.

  1. Integrate

    Multimodal Biological Integration

    Combines blood biomarkers, genetic risk factors, imaging features, physiological signals, and behavioral/digital biomarkers into a single longitudinal profile.

  2. Model

    Dynamic Disease Modeling

    Analyzes longitudinal patterns to identify instability, accelerating decline, and transition risk — modeling disease as a dynamic system rather than a static classification.

  3. Output

    Clinical Intelligence Output

    Generates a stability trajectory, a risk runway, and an interpretable prediction pathway — not just a risk score.

In the workspace

One workspace.Every signal aligned.

Alera sits beside the clinician and the trial team — reading fluid, imaging, genomic, and digital channels as one longitudinal profile, not a pile of PDFs.

Alera Workspace

Stability runway

AR-0142 · Keep watch

BaselineKeep watchCritical
Margin ΨTime →
p-tau217MRI volumeAPOE4GaitNfL

Illustrative interface. Not a clinical product screenshot — a view of how Alera would present a stability runway inside a research or trial-enrichment workspace.

Disease is not a state. Disease is a transition. 

Background: model trajectories approaching a critical transition

See it work

Where thetrajectory turns

Clinical assessment describes where a patient is. Alera describes how a patient is moving — how much perturbation their physiology still absorbs, and how quickly it returns to baseline. The point below marks where that recovery stops keeping up.

  1. Stable

    Physiology absorbs perturbation and returns to baseline.

  2. Fragile

    Recovery slows and variability rises. Clinical assessment still reads as normal.

  3. Critical Transition

    The point at which decline begins to reinforce itself. This is the interval Alera models.

  4. Disease

    Clinically detectable. Conventional diagnosis begins here.

Alera’s framework is described in preprints and is undergoing independent validation. It is a research tool, not a diagnostic device.

Inside the model

What theengine sees

The panels below are drawn from Alera’s research engine rather than illustrated by hand. The system is a dynamical model, not a patient, and the axes carry no clinical units — what they show is the behaviour the engine is built to detect.

Rendered from the research engine on illustrative dynamics. Not clinical data, and not a diagnostic output.

  • Fluid

    p-tau217 · Aβ42/40 · NfL

  • Imaging

    Regional volume · WMH load

  • Genomic

    APOE4 · Polygenic risk

  • Digital

    Gait variability · Keystroke dynamics

  • Clinical

    Chronological and biological age

Many channels, one profile

Fluid, imaging, genomic, digital and clinical measures are aligned onto a single longitudinal profile, so the model reads a person over time rather than a row in a table.

Frequently Asked Questions

A computational platform that models disease progression as a dynamic system, producing a stability trajectory and an estimated intervention window rather than a static risk score.

No. Alera is a research and research-partnership tool, currently used for trial enrichment and patient stratification in pharma R&D contexts — not a clinical decision support or diagnostic device.

The underlying mathematical framework is detailed in preprints and has not yet completed outside peer review. Alera is currently seeking longitudinal clinical datasets and validation partnerships.

Pharmaceutical R&D teams and academic research partners first, for trial enrichment and patient stratification. Hospital-level clinical decision support is a longer-term phase, contingent on validation and a determined regulatory pathway.

Occasional newsletter notes as validation milestones are reached, plus early word on research partnerships. Qualified research and pharma partners may also be contacted directly about pilot collaboration. Subscribing does not grant access to a finished clinical product — there is not one yet.

Newsletter

Stay inthe loop.

Occasional notes on validation milestones, research partnerships, and what we are learning as the model matures. No spam — just the work that matters.

Your details are encrypted at rest, never sold, and used only to send Alera updates you opted into.

Encrypted storage. Confirmation email on subscribe. Unsubscribe anytime.